At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Fingolimoddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of FTY720 for the Treatment of Acute Stroke
In Brief
A Phase 2 clinical trial evaluating Fingolimod for Stroke and 4 related conditions. Completed, enrolled 22 participants across 1 site.
Detailed Summary
Stroke is one of the main severe disease of public health importance. Increasing evidence suggests that inflammatory mechanisms plays a significant role in stroke. So, immune targets are supposed to be an effective one. The sphingosine-1-phosphate receptor regulator Fingolimod(FTY720)is an effective immunology modulator which has been widely used in autoimmune disease and has been testified effective on stoke animal models.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Vascular Accident, Cerebral Stroke, Ischemic Cerebrovascular Accident, Stroke, Acute
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedDec 2013
Primary CompletionOct 2014
TodayJul 2026
First PostedDec 5, 2013
Enrollment StartOct 1, 2012
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.6 years ago
Interventions
Fingolimoddrug
A sphingosine-1-phosphate receptor regulator